Sushmita Panda (@SushmitaPanda) header
Sushmita Panda (@SushmitaPanda) profile picture

Global Pharma Reporter @PharmaScrip, @Norstellaco | Alum: @acjindia | tip/lead: [email protected] | 📩 Signal: Sushmita.33

Delhi, India
Joined August 2011
Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)
Super excited to share that I received an Honorary Mention in the #ProjectSirenAwards2025 for my story "FE Mental Health Series | Every 40 seconds, someone dies by suicide – Can we prevent the next?" Grateful for the recognition!
1/3 🔶 Our next honorary mention goes to @SushmitaPanda for her piece in the E Mental Health series, ‘Every 40 seconds, someone dies by suicide—Can we prevent the next?’ Her story frames suicide as a preventable crisis..
1
1
5
2,534
A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced. wapo.st/4t6oIRy
118
1,584
313
6,161
825,908
Sushmita Panda retweeted
Rasonque booked $197.6m in roughly five weeks to Sept. 30 after its Aug. 26 FDA approval, the best launch-quarter sales for an oncology drug ever. Revolution’s CEO is still tempering expectations. Why? Therapeutic Thursday. Read it here... capsul.news/therapeutic-thur…
1
1
1
30
Sushmita Panda retweeted
After taking over epithelial tumors, ADCs are coming for treating sarcomas! Encouraging phase 1 data with the uPARAP-directed ADC ADCE-D01, with 30% ORR across multiple types of sarcoma. Key tox: neutropenia (requiring growth factors), nausea, IRR. #ENA26
9
2
82
7,261
Sushmita Panda retweeted
So proud to see my colleague Ritika Chopra in this "TIME 100 India" list. The citation covers the spectacular range of her work — education to politics — and flags all the attributes that make it stand apart: hard work, rigour, nurturing sources, all off camera. This is an inspiration for all our formidable young talent in the Express newsroom — and beyond. time.com/collection/time100-…
53
156
18
824
50,668
Sushmita Panda retweeted
In journalism, writer's block often just means you haven't done enough reporting. Conversely, if you can close your eyes & imagine the layout of the piece with some clarity, then it's probably time to start writing
8
86
10
745
41,966
Sushmita Panda retweeted
Story exposing reality of India’s ‘progressive’ abortion law👇🏽 A comment on majority of awful ob-gyn doctors/nurses (mostly women) who don’t seem to have basic training in empathetic, ethical healthcare In any civilised country they would be stripped of licence and penalised
India’s abortion laws promise women the right to make decisions about their own bodies. But inside hospitals, that choice often comes at the cost of humiliation, coercion, delayed treatment, and medical abuse. thenewsminute.com/news/the-c…
1
23
2
70
5,347
Sushmita Panda retweeted
Are you thinking of leaving Delhi-NCR because of the air pollution? Six professionals and founders already did. Here's what they gained, and what it cost them. In today's @IndianExpress 🧵
12
71
10
194
20,703
the @FDA has declined to approve ivonescimab in advanced NSCLC because of lack of OS benefit*. Interesting how the 'culture' of different diseases affects norms and standards for regulatory approval. The landscape of advanced breast cancer treatment would look very different and have different kinetics if OS was required for approval. *this instance may also be affected by the fully ex-US nature of the particular trial smmttx.com/news/press-releas…
10
23
3
97
22,938
Sushmita Panda retweeted
JUST IN: the @FDA has declined to approve PD1/VEGF bispecific ivonescimab in advanced NSCLC with EGFRm, because of lack of OS benefit (via @Reuters) — Having seen approval in several cancers based on PFS, this is somewhat a puzzling rejection. reuters.com/legal/litigation…
8
26
3
105
20,568
FDA is shelving the Commissioner's National Priority Voucher program, according to a Reuters report.
22
13
13
149
52,143
Sushmita Panda retweeted
being a journalist:
1
147
2
905
30,971
Sushmita Panda retweeted
Biopharma CEO "This presentation contains forward-looking statements, as a result of risks and uncertainties..." AI/Tech CEO "We will cure all diseases in less than 10 years"
13
61
5
647
23,486
Sushmita Panda retweeted
Good that you are finally reading a book! Can you please refrain from tweeting about it every 5 mins?
30
67
11
472
19,956
Sushmita Panda retweeted
We now have confirmation the PM2.5 hours that went missing in CPCB records on Diwali were the night's worst. DPCC's updated readings for 30/59 show all above 1,000 µg/m³: Mundka peaked at 3,744, JNU 3,023, Mandir Marg 2,908 and Nehru Nagar 2,808. @htTweets @JasjeevGandhiok
On Diwali night, many of Delhi’s pollution monitors stopped reporting PM2.5 just as readings neared 1,000. At 1am, only 13 of 39 were sending it, though they kept sending other readings. Last year, 29 of the same monitors recorded more than 1,000. @htTweets #Diwali
3
138
12
262
10,951
Breaking: # Firecrackers accounted for 80% of Delhi's #AirPollution hours after #Diwali night, steadily declining between 1 and 9 am. Super work by @iitmpune for sharing this real-time source apportionment data. 🙏 @Priyanshi50 for the alert
9
86
7
204
9,365
Sushmita Panda retweeted
Industry’s share of NHS interventional trial enrollment: 3.8% in 2025/26, down from a high of 13.2% in 2017/18. The ABPI calls the trend “worrying” and offers its reading of the cause. Trial Tuesday. Read it here... capsul.news/trial-tuesday-uk…
1
1
1
29